ERBB2 and breast cancer: Chen et al. [28] performed a retrospective study to evaluate the potential benefit of local treatment in 246 stage IV BC patients and found that local surgery or radiotherapy prolonged OS for Her2-positive (3-year, 41.6% vs 8.8%, p = 0.001) and luminal-like (3-year, 66.4% vs 34.4%, p <0.001) BC patients.